Alise Reicin Joins Merck Serono as Head of Global Clinical Development
Reicin brings extensive experience in R&D as a senior leader in biopharma
Merck Serono announced the appointment of Alise Reicin, MD, as Senior Vice President, Head of Global Clinical Development. Dr. Reicin brings extensive research and early/late clinical development expertise to Merck Serono, including experience in Oncology and Immunology. She is an accomplished pharmaceutical executive with strong leadership ability, having served as a Vice President in various capacities across R&D at MSD (Merck Sharp & Dohme) for the last 10 years.
Alise Reicin, MD
In her role as Head of Global Clinical Development, Reicin will oversee the Clinical Development organization, including the Clinical Development Therapeutic Areas; Evidence Value and Development; Biostatistics; Clinical Operations; and both the Japan and China R&D Hubs. In this capacity, she will lead Merck Serono’s portfolio of pipeline programs.
Reicin’s experience complements the R&D strategy of Merck Serono, which focuses on the core therapeutic areas of oncology, immuno-oncology and immunology with several high-priority programs in late development, such as evofosfamide (TH-302) and avelumab (anti-PD-L1), as well as a number of promising early-stage assets.
Prior to joining Merck Serono, Reicin served as Vice President, Project and Pipeline Leadership, Oncology Franchise at MSD. In this capacity, she led MSD’s PD-1 program and oversaw the initial development and filing activities worldwide, including the first approval in the US. She also managed program leaders across early and late oncology product development teams. During her tenure at MSD, she held roles of increasing responsibility in R&D, including Vice President and Therapeutic Area Head (Bone, Respiratory, Immunology and Endocrinology); Vice President, Research & Early Development (Bone, Respiratory, Immunology and Endocrinology Franchise Integrator); Vice President, Strategic Realization Office; Vice President and Therapeutic Area Head (Clinical Immunology & Analgesia); and Head of a Transformation Task Force for late clinical development.
Before joining MSD, Reicin was a faculty member at Columbia Medical School, and a physician and researcher at Columbia Presbyterian Hospital.
Reicin has a degree in biochemistry from Barnard College of Columbia University. She received her Medical Degree from Harvard Medical School, where she was enrolled in the Health Sciences and Technology program with MIT (Massachusetts Institute of Technology).
Reicin will report to Luciano Rossetti, Head of Global R&D, and serve as a member of the R&D Executive Leadership Team. She will join Merck Serono on May 11, 2015, and be based in Billerica, MA.
Other news from the department people
